Second consensus on medical treatment of metastatic breast cancer.
about
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancerPhase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancerEstrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.Targeting invadopodia to block breast cancer metastasisBrain metastases free survival differs between breast cancer subtypes.The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.Radiofrequency ablation of metastatic lesions from breast cancer.Optimal use of taxanes in metastatic breast cancerEverolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.Prognostic factors in 1,038 women with metastatic breast cancer.International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Maintenance treatment in metastatic breast cancer.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.More options, more considerations: how new treatment options influence clinical decision making.Role of denosumab in breast cancer.A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.Plasma S100P level as a novel prognostic marker of metastatic breast cancer.Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer.In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.Higher rate of breast surgery complications in patients with metastatic breast cancer: an analysis of the NSQIP database.Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
P2860
Q24633167-A3316CE7-8EE2-4C45-85F0-E3BE4C937E2CQ33382437-49E447C6-1AB3-4F41-A0E7-8C9BC6EE80CDQ33408664-07FBB7DD-C85E-419E-AF7D-DBBED9E1B590Q34418413-0995F168-8673-4A6B-BCAF-B448E3B07743Q35584058-A527C1A2-B990-4C5B-A7C4-5E5796C353A5Q35640216-80D65747-1796-48F1-8588-70346A1E07D1Q35739534-7B104C2F-F69F-4B6C-BA39-417FB7BC9442Q36316424-55BCF398-44E5-4F56-B499-4A8978DC20C5Q36502730-232C8BFD-44F0-46B4-A0B5-A2F2FFB5FF1BQ36571156-C13EA6A2-3D39-41AE-845A-A289CDAE33FDQ37225780-24F624E1-4BBE-4D73-92B6-6942C21F3BEDQ37255122-48E129E4-B98A-4E5C-93B9-ECF5C813D3AAQ37321930-CDA0356A-3BC7-42DE-A235-1855B91D5EBAQ37329165-C20CFC67-F84D-4D28-BC0B-834A823847B4Q37338245-0B464394-62E1-4994-9435-84CE692A29EBQ37360151-63D6D2F7-75B2-4149-A8EC-56F5E24E2499Q37411142-F7CED314-C3DB-4220-B981-8AC547859D29Q37571986-00FC99DC-FC8C-43FD-94BC-742F6589E8F3Q38217754-0E24B8DA-099D-4986-9441-843580B3527DQ38978439-A433A809-A431-4107-8EF9-E8F3BE125D5AQ39405526-54559EC0-DD4B-45C6-84DB-1F3989DDCECDQ40768670-2C94BB90-B3AA-4F14-A8D9-9AA4295E42C5Q41035419-8C5B3B7B-04F8-407B-828B-A07EF73FF7A2Q41116986-3AE7667F-50FE-4880-B8C9-2ADD81E6F3C1Q42203621-41EAC2EE-C0F3-438A-9279-30CA9C65FE32Q45952985-9FF14D5C-37DD-4487-A57D-3954419EBF54
P2860
Second consensus on medical treatment of metastatic breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Second consensus on medical treatment of metastatic breast cancer.
@ast
Second consensus on medical treatment of metastatic breast cancer.
@en
type
label
Second consensus on medical treatment of metastatic breast cancer.
@ast
Second consensus on medical treatment of metastatic breast cancer.
@en
prefLabel
Second consensus on medical treatment of metastatic breast cancer.
@ast
Second consensus on medical treatment of metastatic breast cancer.
@en
P2093
P50
P356
P1433
P1476
Second consensus on medical treatment of metastatic breast cancer.
@en
P2093
C C Zielinski
C Wiltschke
E Stadtmauer
H Burstein
H Zwierzina
J Bonneterre
K Possinger
M Stockler
P304
P356
10.1093/ANNONC/MDL155
P577
2006-07-10T00:00:00Z